Access to this article via Institution of Civil Engineers Library is not available. Glucagon-like peptide 1 (GLP-1) receptor agonists are revolutionizing obesity treatment; in the USA, these are now the most prescribed drugs.
Despite their proven efficacy, there is substantial inter-person variability in the degree of weight loss and the severity of side effects. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis Specific combinations of human and viral genetic variants explain a cancer predisposition in southern China The Sharifi Lab seeks postdocs to study endocrine and metabolic mechanisms in GU cancers, driving translational discovery to therapies The Publishing Director role is a key strategic component of the Springer Journals portfolio structure.
Recruitment Positions Professor/Associate Professor/Assistant Professor in Division of Biomedical Health Sciences The UNIVERSITY of OKLAHOMA® College of Medicine Department of Oncology Science Postdoctoral Research Fellow position to study therapeutic resista... IOCB Prague welcomes applications for a Junior Group Leader in computational chemistry An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.
Nature Medicine published a clinical update in Research Highlights on 23 Apr 2026.
The item focuses on Genetics and GLP-1 drug responses.
Review the original article for the full source wording and details.